TY - JOUR
T1 - Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
AU - Schmidt, Fabian
AU - Weisblum, Yiska
AU - Muecksch, Frauke
AU - Hoffmann, Hans Heinrich
AU - Michailidis, Eleftherios
AU - Lorenzi, Julio C.C.
AU - Mendoza, Pilar
AU - Rutkowska, Magdalena
AU - Bednarski, Eva
AU - Gaebler, Christian
AU - Agudelo, Marianna
AU - Cho, Alice
AU - Wang, Zijun
AU - Gazumyan, Anna
AU - Cipolla, Melissa
AU - Caskey, Marina
AU - Robbiani, Davide F.
AU - Nussenzweig, Michel C.
AU - Rice, Charles M.
AU - Hatziioannou, Theodora
AU - Bieniasz, Paul D.
N1 - Generated from Scopus record by KAUST IRTS on 2023-02-15
PY - 2020/7/21
Y1 - 2020/7/21
N2 - The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.
AB - The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.
UR - https://rupress.org/jem/article/217/11/e20201181/151961/Measuring-SARS-CoV-2-neutralizing-antibody
UR - http://www.scopus.com/inward/record.url?scp=85088610301&partnerID=8YFLogxK
U2 - 10.1084/JEM.20201181
DO - 10.1084/JEM.20201181
M3 - Article
SN - 0022-1007
VL - 217
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 11
ER -
